Document is current
Any future updates will be listed below
-
Authors
Terheyden, Jan Henrik
Fink, David J.
Mercieca, Karl
Wintergerst, Maximilian W. M.
Holz, Frank G.
Finger, Robert P.
-
Funding
Funding for this research was provided by:
Universitätsklinikum Bonn
- License Information
-
More Information
Article History
Received: 15 November 2023
Accepted: 25 January 2024
First Online: 8 February 2024
Declarations
:
: This study protocol was reviewed and approved by the Institutional Ethics Committee, University Hospital Bonn, Germany, approval ID 255/22. Written informed consent was obtained from all participants.
: Not applicable.
: JHT: Heidelberg Engineering, Optos, Zeiss, CenterVue, Novartis, Okko.DJF: Heidelberg Engineering, Optos, Zeiss, CenterVue.KM: AJL Ophthalmics, Alcon, Allergan/Abbvie, Bausch & Lomb, IOPtima, FCI, Nova Eye Medical, Okkohealth, Rheon Medical, Santen, Sight Sciences, Thea, Topcon.MWMW: Bayer AG, Berlin-Chemie AG, CenterVue SpA, Carl Zeiss Meditec, Eyenuk, Inc., Eyepress Fachmedien GmbH, glaucare GmbH, Heine Optotechnik GmbH, Heidelberg Engineering, Novartis Pharma GmbH, Optos, Pro Generika e.V., Science Consulting in Diabetes GmbH.FGH: Allergan, Apellis, Astellas, Bayer, Boehringer-Ingelheim, Bioeq/Formycon, CenterVue, Roche/Genentech, Geuder, Grayburg, Gyroscope, Heidelberg Engineering, IvericBio, Janssen, Kanghong, LinBiosciences, NightStarX, Novartis, Optos, Oxurion, Pixium Vision, Stealth BioTherapeutics, Zeiss, Grade Reading Centre.RPF: Alimera, Apellis, Bayer, Boehringer-Ingelheim, Novartis, ODOS, Oxford Innovation, ProGenerika, Roche/Genentech, Biogen, Icare, Heidelberg Engineering, Zeiss Meditec.
